Вплив мультимодальної малоопіоїдної анестезії на динаміку анексину V у плазмі крові хворих, яким виконують кардіохірургічні втручання

С.Р. Маруняк, О.А. Лоскутов, О.М. Дружина, І.Р. Малиш, Н.В. Коротчук

Література   

1. De Jong RCM, Pluijmert NJ, de Vries MR. et al. Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia-reperfusion injury by suppression of the cardiac inflammatory response. Sci Rep. 2018;8(1):6753. doi: 10.1038/s41598-018-25143-y.
2. Ewing MM, de Vries MR, Nordzell M. et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol. 2011;31(1):95–101. doi: 10.1161/ATVBAHA.110.216747.
3. Kenis H, Zandbergen HR, Hofstra L. et al. Annexin A5 uptake in ischemic myocardium: demonstration of reversible phosphatidylserine externalization and feasibility of radionuclide imaging. J Nucl Med. 2010;51(2):259–267. doi: 10.2967/jnumed.109.068429.
4. Laufer EM, Winkens MH, Narula J, Hofstra L. Molecular imaging of macrophage cell death for the assessment of plaque vulnerability. Arterioscler Thromb Vasc Biol. 2009;29(7):1031–1038. doi: 10.1161/ATVBAHA.108.165522.
5. Matsuda R, Kaneko N, Kikuchi M. et al. Clinical significance of measurement of plasma annexin V concentration of patients in the emergency room. Resuscitation. 2003;57(2):171–177. doi: 10.1016/s0300-9572(03)00034-0.
6. Meldrum DR, Donnahoo KK. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. J Surg Res. 1999;85(2):185–199. doi: 10.1006/jsre.1999.5660.
7. Ravassa S, García-Bolao I, Zudaire A. et al. Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovasc Res. 2010;88(2):304–313. doi: 10.1093/cvr/cvq183.
8. Ravassa S, González A, López B. et al. Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. Eur Heart J. 2007;28(22):2785–2791. doi: 10.1093/eurheartj/ehm370.
9. Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53(6):527–532. doi: 10.1007/s000180050067.
10. Ruifrok WT, Westenbrink BD, de Boer RA. et al. Apoptosis during CABG surgery with the use of cardiopulmonary bypass is prominent in ventricular but not in atrial myocardium. Neth. Heart J. 2010;18(5):236–242. doi: 10.1007/BF03091769.
11. Shojaie M, Sotoodah A, Roozmeh S. et al. Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction. Thrombosis J. 2009;7:13. doi: 10.1186/1477-9560-7-13.
12. Van Genderen HO, Kenis H, Hofstra L. et al. Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim Biophys Acta. 2008;1783(6):953–963. doi: 10.1016/j.bbamcr.2008.01.030.
13. Van Heerde WL, Sakariassen KS, Hemker HC. et al. Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. Arterioscler Thromb. 1994;14(5):824–830. doi: 10.1161/01.atv.14.5.824.
14. Wang X, Guo Z, Ding Z, Mehta JL. Inflammation, autophagy, and apoptosis after myocardial infarction. J Am Heart Assoc. 2018;7(9):e008024. doi: 10.1161/JAHA.117.008024.